秒速时时彩

The first public announcement of the public participation in the environmental impact assessment of the upgrading project of the specialty drug substance production center

Posted: May 06, 2019 Posted by: CSPC


1. Project Name: Upgrading and Reconstruction Project of Characteristic API Production Center

2. Project Overview

CSPC Olympiad Pharmaceutical Co., Ltd. completed and completed the assimexin production line, alendronate sodium, amlodipine maleate production line, solvent recovery production line, and traditional Chinese medicine production line for the upgrading and reconstruction of specialty drug substance production centers. 4. Upgrading and reconstruction, newly added 43 main process equipment (sets). After the project is completed, according to market demand, a flexible production method of co-line products will be used to add indomethacin, nitrendipine, and vitamin production capacity to the asimicin production line. Among them, the maximum annual production capacity of indomethacin is 17 t / a. Nitrendi has a maximum annual production capacity of 90t / a, and vitamin BT has a maximum annual production capacity of 12t / a. On the basis of the alendronate sodium and amlodipine maleate production lines, ranitidine hydrochloride, ambroxol hydrochloride, The production capacity of clopidogrel hydrogen sulfate, of which the maximum production capacity of ranitidine hydrochloride is 35t / a, the maximum production capacity of ambroxol hydrochloride is 35t / a, and the maximum production capacity of clopidogrel hydrogen sulfate is 12t / a; Benzene sulfonyl chloride solvent recovery process, adding petroleum ether recovery process, to achieve p-toluene sulfonyl chloride recovery capacity of 200t / a.

On the basis of the existing Chinese medicine production line, a total of 7 new Chinese medicine production lines have been added, of which the maximum production capacity of Huoxiang Qushu extract is 42t / a, the maximum production capacity of Xiangsha Yangwei extract is 66t / a, and the maximum output of Xinnaokang extract is 210t / a. The maximum production capacity of honeysuckle extract is 150t / a, the maximum production capacity of Scutellaria baicalensis extract is 18t / a, the maximum production capacity of Daqingye extract is 69t / a, and the maximum production capacity of isatis root extract is 90t / a; a new Chinese medicine production line is added for formula granule production , The maximum production capacity of formula particles is 280t / a. The total investment of the project is 40 million yuan.

3. Construction unit and contact information

Construction unit: CSPC Ouyi Pharmaceutical Co., Ltd.

Contact: Li Shaofang

Li Shaofang Telephone: 15393095532

4. Name of the entity preparing the environmental impact report

Hebei Qizheng Environmental Technology Co., Ltd.

5. Main matters for public comment

In order to listen to the opinions and suggestions from various circles of society on the environmental protection of the upgrading project of the characteristic raw material drug production center, the project will be publicized, soliciting the public's valuable ideas and suggestions. Non-environmental protection content is outside the scope of this solicitation.

6. The main ways of public comments

From now on, the public can send a letter to the designated address (delivery address: 88 Yangzi Road, Shijiazhuang Economic and Technological Development Zone, phone: 15393095532, recipient: Li Shaofang), or other methods provided by the construction unit, and publish it within the prescribed time. For comments on engineering construction and environmental assessment, please provide detailed contact information and real name when expressing your opinions, so as to facilitate timely response to your comments.

Public comment form web link

Link: http://pan.baidu.com/s/1iKKMbXBzUlK9IRLZJfz5BQ

7. Publicize the start and end time

May 6, 2019 to May 17, 2019.

CSPC Ouyi Pharmaceutical Co., Ltd.

May 6, 2019